Aurobindo Subsidiary Eugia Launches Generic Pomalyst Capsules in US
New Delhi: Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market.
The product is the generic equivalent of Pomalyst Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.
According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.
Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
